Physician profile
Ada Noh
NPI 1811371693
$74,371.43
in general payments reported to CMS, 2019-2025
22 companies · $69K in 2025
The $69K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $88.43 · 2021: $222 · 2022: $64.31 · 2023: $255 · 2024: $4,580 · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $34K · Travel and Lodging: $15K · Consulting Fee: $12K · Food and Beverage: $9,096 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $34,125.00 |
| Travel and Lodging | $15,367.01 |
| Consulting Fee | $11,875.00 |
| Food and Beverage | $9,096.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $52,454.75 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $10,622.47 | 2024-2025 | Tryptyr, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $5,746.03 | 2024-2025 | Xdemvy |
| Nordic Pharma, INC. | $1,400.00 | 2025 | Lacrifill |
| Bausch & Lomb Americas INC. | $1,298.22 | 2023-2025 | Miebo, Xiidra, Lotemax |
| Harrow Eye, LLC | $850.55 | 2024-2025 | Vevye |
| Abbvie INC. | $661.07 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $331.70 | 2019-2022 | |
| Biotissue Holdings INC. | $176.78 | 2025 | |
| Oyster Point Pharma, INC. | $152.72 | 2024-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $151.61 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $145.79 | 2021-2024 | |
| Amgen INC. | $120.68 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $98.32 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $37.50 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heidelberg Engineering, INC. | $24.78 | 2022 | |
| Sight Sciences, INC. | $20.82 | 2025 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $20.62 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Mallinckrodt Hospital Products INC. | $13.45 | 2024 | Acthar |
| Allergan, INC. | $12.34 | 2021 | |
| Optos, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ada Noh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.